Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxapram versus placebo in preterm newborns
2024-515625-29-00Phase 3Authorised
- Sponsor
- Erasmus MC
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in apnea of prematurity (AOP) comparing Doxapram with Placebo (2 arms). Primary endpoint: Composite of death or severe disability at 18–24 months corrected age. Planned start Nov 2024; status: authorised.
02
Drugs
doxapram
03
Conditions
apnea of prematurity (AOP)
Beyond the preview
Go deeper on 2024-515625-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515625-29-00.